Jacob Mathew, MD
Internal Medicine · Bremerton, WANPI 1710141346
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,600 of the $6,669 with a category attached, or 84.0%. E.r. Squibb & Sons, L.L.C. accounts for 88.1% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2020 at $4,059 and has fallen 95.8% since, to $170 in 2025. Among internal medicine clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 20 payments — averaging $333.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$6K
- AstraZeneca$135
- AbbVie$130
- Johnson & Johnson$118
- Genentech USA, Inc.$118
- Sanofi$112
- plus $178 from 3 others
Across 11 payments — averaging $451.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$4K
- Merck$962
What the payments were for
- Consulting fees$5,60084%
- Food & beverage$95114%
- Education$1182%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 9 | $5,879 |
| AstraZeneca | 2 | $135 |
| AbbVie | 2 | $130 |
| Johnson & Johnson | 1 | $118 |
| Genentech USA, Inc. | 1 | $118 |
| Sanofi | 2 | $112 |
| Genmab U.S., Inc. | 1 | $105 |
| Amgen | 1 | $59 |
| Bristol Myers Squibb | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,669 in reported general payments places this provider in the 95th percentile of 2,038 internal medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 37 | $996,903 |
| VyndamaxTafamidis | 31 | $684,803 |
| ErleadaApalutamide | 37 | $576,609 |
| JakafiRuxolitinib Phosphate | 29 | $515,857 |
| PomalystPomalidomide | 25 | $514,081 |
| Lenalidomide | 32 | $432,801 |
| RevlimidLenalidomide | 20 | $366,896 |
| CalquenceAcalabrutinib Maleate | 20 | $308,382 |
| Abiraterone Acetate | 170 | $297,499 |
| VerzenioAbemaciclib | 19 | $295,797 |
| VenclextaVenetoclax | 26 | $282,669 |
| BrukinsaZanubrutinib | 23 | $213,687 |
| ImbruvicaIbrutinib | 13 | $213,145 |
| IbrancePalbociclib | 12 | $189,791 |
| TabrectaCapmatinib Hydrochloride | 11 | $180,313 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada, Zytiga, Xarelto | $118 | $788,014116 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $5,879 | $617,41438 claims |
| Bristol Myers SquibbRevlimid | $14 | $366,89620 claims |
| AstraZenecaCalquence | $135 | $308,38220 claims |
| AbbVieVenclexta | $130 | $282,66926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,038 internal medicine providers in Washington.
Other internal medicine in Bremerton
- William BauerBremerton$11K
- Donald SharmanBremerton$6K
- Peter ShalitSeattle$1M
- Lawrence LoebBellevue$784K
- Shawna PurcellOlympia$294K
- Scott RamseySeattle$230K
- Michael CairnsSeattle$144K
- Peiqing QianSeattle$117K
- Alan KellySpokane Valley$96K
- Emily EgdaminWenatchee$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.